Risk Factors for Intraocular Inflammation After Brolucizumab Treatment

JAMA Ophthalmol. 2022 Jan 1;140(1):28-29. doi: 10.1001/jamaophthalmol.2021.4586.
No abstract available

MeSH terms

  • Angiogenesis Inhibitors / therapeutic use
  • Antibodies, Monoclonal, Humanized* / adverse effects
  • Humans
  • Inflammation / drug therapy
  • Risk Factors
  • Uveitis* / chemically induced
  • Uveitis* / drug therapy

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal, Humanized
  • brolucizumab